Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product ...

Royalty Pharma’s valuation remains attractive, supported by sector momentum and sustained capital returns. Click here to know ...

Richard R. Redfern, M.S., C.P.G. No. 10717, an independent Consulting Geologist for Fairchild and a "qualified person" as defined in NI 43-101, has reviewed and approved the scientific and technical ...

Darren Hall, Chief Executive Officer of Equinox Gold, commented: “With our strengthened balance sheet, Equinox Gold is pleased to announce the initiation of a quarterly cash dividend that reflects our ...

Some Roman Catholic parishes are reporting rising membership for the first time in years, and it appears a new generation of worshippers is starting to fill the pews.